Citations

Clear

1134 citation(s) found for "Li, Yan".

Oncolytic viral therapy: a review and promising future directions
Reddy, Ramya , Yan, Sandra C., Segherlou, Zahra Hasanpour , Hosseini-Siyanaki, Mohammad-Reza , Poe, Jordan , Perez‐Vega, Carlos , Lucke‐Wold, Brandon , Chiocca, E Antonio

Mayo Clinic

Journal of Neurosurgery | August 26, 2023 | Volume: 140 | Issue: 2 | Pages: 319-327

10.3171/2023.6.jns23243 | PMID 37877961 Get It

Oncolytic viral therapy is quickly emerging as a promising subset of immunotherapy, which theoretically can target tumor cells while sparing surrounding healthy cells by harnessing the replication machinery of viruses with tropism for tumor cells, resulting in direct oncolysis, and by transforming immunologically "cold" tumor into areas that elicit the host’s immune response. This review provides an overview of oncolytic viral therapy until the present day, starting with the original concept in 1912. The general mechanism of oncolytic viruses (OVs) depends on selectively integrating them into tumor cells based on genetic engineering of viral genomic material, inducing oncolysis and eliciting the host’s innate immune response. Moreover, a major component of oncolytic viral therapy has been herpes simplex virus, with talimogene laherparepvec being the only FDA-approved oncolytic viral therapy for the treatment of melanomas. This review explores the characteristics, advantages, disadvantages, and therapeutic uses of several DNA and RNA viral families. A snapshot of the oncolytic viral treatments used in the most recent and advanced clinical trials is also provided. Lastly, the challenges of implementing oncolytic viral therapy are explored, both at a molecular and clinical level, with a highlight of promising future directions. In particular, the lack of an optimal delivery method based on tumor type for oncolytic viral therapy poses a significant obstacle, even in clinical studies. Intrathecal continuous delivery of OVs is a promising prospect, potentially by adapting the novel continuous irrigation and drainage IRRAflow catheter. Further exploration and testing of the IRRAflow catheter should be undertaken.
TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation
Dreyfus, Julien , Galloo, Xavier , Heitzinger, Gregor , Benfari, Giovanni , Kresoja, Karl-Patrick, Juarez-Casso, Fernando M. , Omran, Hazem , Russo, Giulio , Topilsky, Yan , Weber, Marcel, Sala, Alessandra , Eixerés‐Esteve, Andrea , Riant, Elisabeth , Donal, Erwan , Hausleiter, Jörg , Badano, Luigi P. , Coisne, Augustin , Windecker, Stephan , Zamorano, José Luis , Tang, Gilbert H L, Webb, John G. , Muraru, Denisa , Nejjari, Mohammed , Bonis, Michele De , Carnero, Manuel , Nickenig, Georg, Pfister, Roman , Tribouilloy, Christophe , Rudolph, Volker , Lurz, Philipp , Bartko, Philipp E. , Messika–Zeitoun, David , investigators, TRIGISTRY, Heitzinger, Gregor, Bohbot, Yohan, Topilsky, Yan , Weber, Marcel, Lim, Pascal , Bazire, Baptiste , Donal, Erwan, Tourneau, Thierry Le, Modine, Thomas, Doguet, Fabien , Ajmone-Marsan, N, Stolz, Lukas, Praz, Fabien, Zamorano, José Luís , Bardeleben, Ralph Stephan von, Tang, Gilbert H L, Lubos, Edith, Webb, John A., Schöfer, Joachim, Fam, Neil , Lauten, Alexander , Pedrazzini, Giovanni , Rodés‐Cabau, Josep , Gavazzoni, Mara , Flagiello, Michele, Radu, Costin , Mbaki, Yannick, Tomasi, Jacques , Sénage, Thomas , Chan, Vincent, Alessandrini, Hannes , Eyharts, Damien , Viau, F , Himbert, Dominique , Sievert, Horst, Eggenspieler, Florian , Nicol, Martin , Nickenig, Georg , Pfister, Romain, Crestanello, Juan, Maisano, Francesco, Messika-Zeitoun, David, Kresoja, Karl-Patrik , Heitzinger, Gregor , Juarez-Casso, Fernando, Omran, Hazem , Russo, Giulio , Topilsky, Yan , Nombela-Franco, Luis , Riant, Elisabeth , Donal, Erwan , Hausleiter, Jörg , Coisne, Augustin , Praz, Fabien , Windecker, Stephan , Nejjari, Mohammed , Chan, Vincent , De Bonis, Michele , Carnero-Alcazar, Manuel , Pfister, Roman , Tribouilloy, Christophe , Rudolph, Volker , Lurz, Philipp , Maisano, Francesco , Messika-Zeitoun, David , Enriquez-Sarano, Maurice , Benfari, Giovanni , Kresoja, Karl-Patrik , Taramasso, Maurizio , Bohbot, Yohann , Iliadis, Christos , Weber, Marcel , Nombela‐Franco, Luis , Iung, Bernard , Obadia, Jean‐François , Estévez‐Loureiro, Rodrigo , Tourneau, Thierry Le , Modine, Thomas , Latib, Azeem , Praz, Fabien , von Bardeleben, Ralph Stephan , Tang, Gilbert H L, Hahn, Rebecca T , Chan, Vincent , Crestanello, Juan A. , Maisano, Francesco , Bax, Jeroen J. , Enriquez‐Sarano, Maurice , investigators, TRIGISTRY, Heitzinger, Gregor, Weber, Marcel, Donal, Erwan, Tourneau, Thierry Le, Modine, Thomas, Lavie-Badie, Yoan , Habib, Gilbert , Selton‐Suty, Christine , Stolz, Lukas , Praz, Fabien, Bardeleben, Ralph Stephan von, Ruf, Tobias Friedrich , Tang, Gilbert H L, Webb, John, Michelena, Héctor I. , Solı́s, Jorge , Flagiello, Michele, Chan, Vincent, Rahmouni, Kenza , Viau, Florence, Pfister, R, Crestanello, Juan, Maisano, Francesco, Messika-Zeitoun, David

Mayo Clinic

European Heart Journal | August 24, 2023 | Volume: 45 | Issue: 8 | Pages: 586-597

10.1093/eurheartj/ehad585 | PMID 37624856 Get It

Abstract Background and aims Benefit of tricuspid regurgitation (TR) correction and timing of intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter intervention to conservative management according to a TR clinical stage as assessed using the TRI-SCORE. Methods A total of 2,413 patients with severe isolated functional TR were enrolled in TRIGISTRY (1217 conservatively managed, 551 isolated tricuspid valve surgery, and 645 transcatheter valve repair). The primary endpoint was survival at 2 years. Results The TRI-SCORE was low (≤3) in 32%, intermediate (4–5) in 33%, and high (≥6) in 35%. A successful correction was achieved in 97% and 65% of patients in the surgical and transcatheter groups, respectively. Survival rates decreased with the TRI-SCORE in the three treatment groups (all P < .0001). In the low TRI-SCORE category, survival rates were higher in the surgical and transcatheter groups than in the conservative management group (93%, 87%, and 79%, respectively, P = .0002). In the intermediate category, no significant difference between groups was observed overall (80%, 71%, and 71%, respectively, P = .13) but benefit of the intervention became significant when the analysis was restricted to patients with successful correction (80%, 81%, and 71%, respectively, P = .009). In the high TRI-SCORE category, survival was not different to conservative management in the surgical and successful repair group (61% and 68% vs 58%, P = .26 and P = .18 respectively). Conclusions Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.
Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas
Saberzadeh-Ardestani, Bahar , Graham, Rondell P. , McMahon, Sara , Ahanonu, Eze , Shi, Qian , Williams, Crystal , Hubbard, Antony , Zhang, Wenjun , Murányi, Andrea , Yan, Dongyao , Shanmugam, Kandavel , Jin, Zhaohui , Shanmugam, Kandavel , Sinicrope, Frank A , Graham, Rondell P , Shi, Qian , Jin, Zhaohui , Sinicrope, Frank A.

Mayo Clinic

Clinical Cancer Research | August 11, 2023 | Volume: 29 | Issue: 20 | Pages: 4268-4277

10.1158/1078-0432.ccr-23-1109 | PMID 37566222 Get It

Abstract Purpose: Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) interaction has led to durable responses in fewer than half of patients with mismatch repair–deficient (MMR-d) advanced colorectal cancers. Immune contexture, including spatial distribution of immune cells in the tumor microenvironment (TME), may predict immunotherapy outcome. Experimental Design: Immune contexture and spatial distribution, including cell-to-cell distance measurements, were analyzed by multiplex immunofluorescence (mIF) in primary colorectal cancers with d-MMR (N = 33) from patients treated with anti–PD-1 antibodies. By digital image analysis, density, ratio, intensity, and spatial distribution of PD-L1, PD-1, CD8, CD3, CD68, LAG3, TGFβR2, MHC-I, CD14, B2M, and pan-cytokeratin were computed. Feature selection was performed by regularized Cox regression with LASSO, and a proportional hazards model was fitted to predict progression-free survival (PFS). Results: For predicting survival among patients with MMR-d advanced colorectal cancer receiving PD-1 blockade, cell-to-cell distance measurements, but not cell densities or ratios, achieved statistical significance univariately. By multivariable feature selection, only mean number of PD-1+ cells within 10 μm of a PD-L1+ cell was significantly predictive of PFS. Dichotomization of this variable revealed that those with high versus low values had significantly prolonged PFS [median not reached (>83 months) vs. 8.5 months (95% confidence interval (95% CI), 4.7–NR)] with a median PFS of 28.4 months for all patients [adjusted HR (HRadj) = 0.14; 95% CI, 0.04–0.56; P = 0.005]. Expression of PD-1 was observed on CD8+ T cells; PD-L1 on CD3+ and CD8+ T lymphocytes, macrophages (CD68+), and tumor cells. Conclusions: In d-MMR colorectal cancers, PD-1+ to PD-L1+ receptor to ligand proximity is a potential predictive biomarker for the effectiveness of PD-1 blockade.
Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS and energy needs via ME1 upregulation
Gicobi, Joanina K. , Mao, Zhiming , DeFranco, Grace , Li, Ying , Hirdler, Jacob, Vianzon, Vianca , Abraha, Feven , Harmsen, William S. , Yan, Yiyi , Dronca, Roxana , Zhu, Mojun , Wu, Xiaosheng , Owen, Dawn , Orme, Jacob J. , Liu, Xin , Hirdler, Jacob B. , Vianzon, Vianca V , Dellacecca, Emilia R. , Hsu, Michelle A. , Barham, Whitney , Kim, Yohan , Markovic, Svetomir N. , Mansfield, Aaron S. , Lin, Yi , Grams, Michael P. , Lucien, Fabrice , Zeng, Hu , Park, Sean S. , Dong, Haidong

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 157.06-157.06

10.4049/jimmunol.210.supp.157.06 Get It

Abstract Cytotoxic T lymphocytes (CTL) are indispensable in anti-tumor immunity. Although CTLs are prone to exhaustion in patients with advanced cancer, T cell resiliency explains the presence of tumor-reactive CTLs that are less exhausted, capable of cytolytic function, expansion, and rebound in response to immunotherapy to reject metastatic malignancies. However, the features of resilient T cells have not been clearly defined. In this report, we demonstrate that peripheral CX3CR1+ CD8+ T cells with low mitochondrial membrane potential rebounded CTL function quickly after radiation therapy in patients with large tumor burden portraying their functional resiliency. Furthermore, CX3CR1+ CD8+ T cell with low, but not high, mitochondrial membrane potential are highly cytotoxic, accumulate less reactive oxygen species (ROS), and express more Malic enzyme 1 (ME1). ME1 overexpression increases ATP production in a glycolysis-independent manner while concurrently curtailing excessive ROS in activated CD8+ T cells; and expands CX3CR1+NKG7+ effector CD8+ T cells with enhanced cytotoxicity. Importantly, transfection of ME1 mRNA promotes tumoricidal activity in CD8+ T cells from patients with advanced cancers. Our study reveals a mechanism used by CTLs to balance excessive ROS via ME1 to maintain a metabolic and functional resiliency. Modification of ME1 expression in CTLs may be a novel method to improve the efficacy of cancer immunotherapy by preventing T cell exhaustion. Supported by grants from Mayo Clinic Foundation and NIH (R01CA 256927-2)
DUSP2 functions as a negative regulator of cytotoxic T cell responses in cancer immunotherapy
Liu, Xin , Gicobi, Joanina K. , Yan, Yiyi , Hirdler, Jacob B. , Dellacecca, Emilia R. , Barham, Whitney , Li, Ying , Dong, Haidong

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 171.06-171.06

10.4049/jimmunol.210.supp.171.06 Get It

Abstract Only a small cohort of patients show durable responses to immune checkpoint inhibitor (ICI) therapy and the mechanisms regulating CD8 T cell responses to ICIs are yet to be elucidated. To that end, we explored T cell intrinsic factors that may be attributed to low ICI therapy response rates. We have identified Dual Specificity Phosphatase 2 (DUSP2) as a potential negative regulator of ICI response within CD8 T cells. We demonstrated that DUSP2 expression in human CD8 T cells is transient, peaking at two-hours post-T cell stimulation with rapid waning thereafter. Downregulation of DUSP2, via siRNA transfection, increased cytotoxicity of human CD8 T cells activated for 48-hours prior to inclusion in a four-hour tumor killing co-culture assay, despite the return of DUSP2 expression to baseline levels at this time-point. Additionally, DUSP2 overexpression, via mRNA transfection, decreased release of effector molecules (Granzyme B and Interferon-gamma) from human CD8 T cells at 24-hours post-activation when compared to control mRNA. When we utilized RNA-sequencing to analyze and compare differentially expressed genes between responders and non-responders of ICI therapy, we found DUSP2 expression in CX3CR1 positive CD8 T cells to be consistently decreased in responders but not in non-responders. Since CX3CR1 positive CD8 T cells identify a highly resilient and cytotoxic subset in response to ICI therapy, we hypothesize that DUSP2 negatively regulates ICI-responsive effector CD8 T cells. Thus, uncovering the role of DUSP2 in CD8 T cells may provide a target to improve the efficacy of ICIs in patients with limited therapeutic alternatives. Mayo Clinic Department of Immunology Pilot Award Mayo Clinic Center for Individualized Medicine
Complete tolerogenic response adjuvant stimulates Treg response to immunization
Janjam, Sri Sushma Santhi, Geng, Yajun, Shin, Soo Min, Joshi, Kanak , Panicker, Anjali J. , Shankar, Archana , Elangovan, Ramya , Koehler, Jason , Gnanasekar, Varun , Williams, Amanda , Feng, Addysen, ellis, Christian, Vattikota, Anirudh, Chen, Aoshuang, Yan, Zhaoqi , Koehler, Jason , Zheng, Guoxing

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 158.08-158.08

10.4049/jimmunol.210.supp.158.08 Get It

Abstract We identified the lowest composition necessary to generate a vaccination adjuvant that promotes a Treg response following immunization in mice and named it “complete tolerogenic adjuvant.” This novel adjuvant may allow us to utilize the well-established “antigen plus adjuvant” method of vaccination to induce Treg cell-mediated antigen-specific immunosuppression. The minimal composition is dexamethasone, rapamycin, and monophosphoryl lipid A with the following mass ratios: 8:20:3. We have demonstrated why immunosuppressive and immunogenic substances are both required for the formation of genuine adjuvants for Treg cells by dissecting the roles of each of these components during vaccination. Currently, research is ongoing in our group to begin to assess the usefulness of this adjuvant for antigen immunization in murine models of human autoimmune/inflammatory diseases. Specifically, we are evaluating the tolerogenic efficacy of this adjuvant for vaccination regimen targeting the apolipoprotein B antigen, using the ApoE−/− mouse model of atherosclerosis. These studies are expected to help drive the development of further, perhaps more effective, complete tolerogenic adjuvants that could be used to create a plethora of new, novel vaccines for treating immunological illnesses. Master program and NIH grant
Cobind: quantitative analysis of the genomic overlaps
Ma, Tao , Guo, Lingyun, Yan, Huihuang , Wang, Liguo , Wang, Liguo , Ma, Tao

Mayo Clinic

Bioinformatics Advances | August 7, 2023 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/bioadv/vbad104 | PMID 37600846 Get It

Abstract Motivation Analyzing the overlap between two sets of genomic intervals is a frequent task in the field of bioinformatics. Typically, this is accomplished by counting the number (or proportion) of overlapped regions, which applies an arbitrary threshold to determine if two genomic intervals are overlapped. By making binary calls but disregarding the magnitude of the overlap, such an approach often leads to biased, non-reproducible, and incomparable results. Results We developed the cobind package, which incorporates six statistical measures: the Jaccard coefficient, Sørensen–Dice coefficient, Szymkiewicz–Simpson coefficient, collocation coefficient, pointwise mutual information (PMI), and normalized PMI. These measures allow for a quantitative assessment of the collocation strength between two sets of genomic intervals. To demonstrate the effectiveness of these methods, we applied them to analyze CTCF’s binding sites identified from ChIP-seq, cancer-specific open-chromatin regions (OCRs) identified from ATAC-seq of 17 cancer types, and oligodendrocytes-specific OCRs identified from scATAC-seq. Our results indicated that these new approaches effectively re-discover CTCF’s cofactors, as well as cancer-specific and oligodendrocytes-specific master regulators implicated in disease and cell type development. Availability and implementation The cobind package is implemented in Python and freely available at https://cobind.readthedocs.io/en/latest/.
Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
Sun, Rui , Yan, Binyuan , Li, Hao , Ding, Donglin , Wang, Liguo , Pang, Jun , Ye, Dingwei , Huang, Haojie , Sun, Rui , Wang, Liguo , Huang, Rui , Yan, Binyuan , Pang, Jun , Ding, Donglin , Sun, Rui

Mayo Clinic

Cancer Research | August 1, 2023 | Volume: 83 | Issue: 19 | Pages: 3192-3204

10.1158/0008-5472.can-23-0285 | PMID 37527336 Get It

Abstract Androgen receptor (AR) inhibition by androgen deprivation and/or antiandrogen administration is the mainstay therapy for advanced prostate cancer. However, most prostate cancers ultimately become resistant to these therapies, indicating the importance of identifying mechanisms driving resistance to improve patient outcomes. Here we demonstrated that acute treatment with the antiandrogen enzalutamide (ENZ) decreased glutathione (GSH) production, increased lipid peroxidation, and induced ferroptosis in prostate cancer cells. Consistently, meta-analysis of transcriptomic data linked the androgen-AR axis to metabolism-related biological processes, including lipid metabolism. The cystine transporter gene SLC7A11 was a key AR target, and full-length AR (AR-FL) transactivated SLC7A11 transcription by directly occupying the SLC7A11 promoter and putative enhancer regions. AR variants (AR-V) preferentially bound the SLC7A11 enhancer and upregulated SLC7A11 expression, thereby conferring resistance to ferroptosis induced by ENZ treatment. However, this effect was abolished following downregulation of AR-Vs using the dual CBP/p300 and BET inhibitor NEO2734. These findings reveal ferroptosis induction as an anticancer mechanism of antiandrogens and SLC7A11 as a direct target gene of AR-FL and AR-Vs. AR-V-mediated SLC7A11 expression represents a mechanism coupling ferroptosis resistance to prostate cancer progression. Significance: Upregulation of SLC7A11 can be induced by androgen receptor variants to inhibit antiandrogen-induced prostate cancer cell ferroptosis and to drive castration resistance in prostate cancer.
Pilot Study: Personalized Medicine in Endoscopy, Can Pharmacogenomics Predict Response to Conscious Sedation?
Zaver, Himesh B. , Ghoz, Hassan , Malviya, Balkishan, Bali, Aman S. , Antwi, Samuel O. , Moyer, Ann M. , Bi, Yan , Moyer, AM , Bali, Aman , Antwi, Samuel O , Bi, Yan

Mayo Clinic

Journal of Personalized Medicine | July 10, 2023 | Volume: 13 | Issue: 7 | Pages: 1107

10.3390/jpm13071107 | PMID 37511720 Get It

Background: Adequate response to moderate (conscious) sedation varies significantly between individuals. Polymorphisms in genes encoding drug metabolizing enzymes can lead to inter-individual variability in drug efficacy, potentially influencing sedation requirements during endoscopic procedures. Objectives: The aim of this study was to assess the potential role of inter-individual variation in inherited polymorphisms of drug-metabolizing enzymes, cytochrome P450 (CYP450), specifically CYP3A4 and CYP3A5, in sedation requirements for outpatient endoscopic procedures. Methods: A retrospective analysis of sedation requirements and pharmacogenomics data in 106 unique patients who received outpatient esophagogastroduodenoscopy (EGD), colonoscopy, or both between December 2011 and February 2019 was conducted. Patients were divided into two groups based on their sedation requirements during endoscopy (high vs. normal sedation). Results: Patients with reduced a CYP2C19 metabolism (poor + intermediate metabolizers) (odds ratio [OR] = 0.38, 95% confidence interval [CI]: 0.16–0.91, p = 0.03), poor CYP3A5 metabolism (OR = 0.25, 95% CI: 0.095–0.65, p = 0.0046), and poor UGT1A1 (OR = 2.76, 95% CI: 1.07–7.13, p = 0.08) had higher odds of requiring normal sedation compared to those with CYP2C19 increased metabolism, CYP3A5 intermediate metabolism, and UGT1A1 intermediate metabolism. Conclusion: Information about inter-individual variation in (CYP450) genes may be useful for determining the sedation requirements for outpatient endoscopic procedures. We found that patients with reduced CYP2C19 metabolism, poor CYP3A5 metabolism, and poor UGT1A1 metabolism were more likely to require normal sedation requirements during outpatient endoscopic procedures.
Do Early Relapses Predict the Risk of Long‐Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD ?
Chen, Bo , Gómez‐Figueroa, Enrique , Redenbaugh, Vyanka , Satukijchai, Chanjira , Messina, Silvia , Sá, Mário , Woodhall, Mark , Paul, Friedemann , Robertson, Neil P. , Lim, Ming , Wassmer, Evangeline , Kneen, Rachel , Huda, Saif , Blain, Camilla, Halfpenny, Christopher , O’Sullivan, Eoin , Hobart, Jeremy , Fisniku, Leonora , Martin, Roswell , Cooper, Sarah , Williams, Victoria , Chen, John J. , Pittock, Sean J. , Ramdas, Sithara , Leite, Maria Isabel , Geraldes, Ruth , Palace, Jacqueline , Pittock, S J , Messina, Silvia , Sa, Mario , Lim, Ming , Dobson, Ruth , Chen, John J , Paul, Friedemann , Geraldes, Ruth , Palace, Jacqueline , Wassmer, Evangeline , Francis, Anna G. , Wu, Yan Ting , Hemingway, Cheryl , Williams, Victoria, Waters, Patrick , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | July 3, 2023 | Volume: 94 | Issue: 3 | Pages: 508-517

10.1002/ana.26731 | PMID 37394961 Get It

Objective Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) can be monophasic or relapsing, with early relapse being a feature. However, the relevance of early relapse on longer‐term relapse risk is unknown. Here, we investigate whether early relapses increase longer‐term relapse risk in patients with MOGAD. Methods A retrospective analysis of 289 adult‐ and pediatric‐onset patients with MOGAD followed for at least 2 years in 6 specialized referral centers. “Early relapses” were defined as attacks within the first 12 months from onset, with “very early relapses” defined within 30 to 90 days from onset and “delayed early relapses” defined within 90 to 365 days. “Long‐term relapses” were defined as relapses beyond 12 months. Cox regression modeling and Kaplan–Meier survival analysis were used to estimate the long‐term relapse risk and rate. Results Sixty‐seven patients (23.2%) had early relapses with a median number of 1 event. Univariate analysis revealed an elevated risk for long‐term relapses if any “early relapses” were present (hazard ratio [HR] = 2.11, p < 0.001), whether occurring during the first 3 months (HR = 2.70, p < 0.001) or the remaining 9 months (HR = 1.88, p = 0.001), with similar results yielded in the multivariate analysis. In children with onset below aged 12 years, only delayed early relapses were associated with an increased risk of long‐term relapses (HR = 2.64, p = 0.026). Interpretation The presence of very early relapses and delayed early relapses within 12 months of onset in patients with MOGAD increases the risk of long‐term relapsing disease, whereas a relapse within 90 days appears not to indicate a chronic inflammatory process in young pediatric‐onset disease. ANN NEUROL 2023;94:508–517